RB1 and breast carcinoma: CDK4/6 inhibitors are currently widely used in the treatment of breast cancer but only used in patients with ERα-positive breast cancer because of their frequent overexpression of cyclin D. At the same time, most HER2-negative breast cancers have RB1 mutations and/or loss, limiting the use of CDK4/6 inhibitors (102).